Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

News | Atrial Fibrillation

May 18, 2018 — Catheter ablation for atrial fibrillation (AF) in patients with heart failure in the CASTLE-AF Trial was ...

Home May 18, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral ...

Home May 18, 2018
Home
News | Atrial Fibrillation

 


May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in ...

Home May 18, 2018
Home
Heart Rhythm Society (HRS) live electrophysiology (EP) procedure case at the 2018 annual meeting. #HRS2018
Feature | HRS | Dave Fornell

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Heart Rhythm Society (HRS) Scient ...

Home May 18, 2018
Home
Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018
Feature | Atrial Fibrillation

May 16, 2018 – The first results of the randomized, multicenter, long-term, international CABANA clinical trial were ...

Home May 17, 2018
Home
News | Ablation Systems

May 17, 2018 — Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 ...

Home May 17, 2018
Home
Technology | Patient Monitors

May 16, 2018 — Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care ...

Home May 16, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and new ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricular ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception and ...

Home May 15, 2018
Home
News | Atrial Fibrillation

May 11, 2018 — A new study finds that integrating two separate clinical risk score models more accurately helps ...

Home May 11, 2018
Home
News | ECG Monitoring Services

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large study evaluating online versus offline electroc ...

Home May 09, 2018
Home
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
Home
Technology | EP Mapping and Imaging Systems

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD Grid ...

Home May 03, 2018
Home
Subscribe Now